Flibanserin

This classification denotes a serotonin antagonist with the molecular formula C20H21F3N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37JK4STR6Z, chemically known as 1,3-dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2h-benzimidazol-2-one but generally known as flibanserin, which bears US NIH Compound Identifier 127941. European Medicines Agency schedules Flibanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07644MIG. The term FLIBANSERIN is an International Non-Proprietary Name. FLIBANSERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flibanserin under HS 29335995 and SITC 51576. As of Q4 2014, FLIBANSERIN remains the US FDA Preferred Term for this commodity. Flibanserin bears US NLM identifiers UMLS ID C0754280 and NCI Concept Code C80769. SMILES: FC(F)(F)c1ccc(N2CCN(CC2)CCn2c3c([nH]c2=O)cccc3)cc1.